The presentation will highlight the hallmarks of immuno-oncology drug development and expand on pharmacometrics, clinical pharmacology and statistical strategies to optimize clinical trial design and development of immune-oncology drugs. This will be the first webinar of a three-part series on immune-oncology drug development. Highlights of this session will include:
• Fundamental biology underpinnings and trajectory of immune-oncology drug development and how this differs from the standard clinical development paradigm in oncology.
• Role and impact of clinical pharmacology aspects to support immune-oncology drug development for monotherapy and combination.
• Modeling and simulation strategies and clinical trial designs for early development and pivotal trials.